Prediction of Peritoneal Metastasis for Gastric Cancer Based on Radiomics
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorChinese Academy of Sciences
About this trial
Peritoneal metastasis of gastric cancer is difficult to be detected in time, thus delaying treatment. Based on the conventional CT images of gastric cancer, this study plans to develop, improve and validate an intelligent analysis system based on radiomics. By extracting and combining the radiomics features related to peritoneal metastasis of gastric cancer, the intelligent analysis system could predict the risk of peritoneal metastasis, and provide personalized decision suggestions for the treatment of gastric cancer.
Eligibility criteria
Qualifiers
(1) diagnosed advanced gastric cancer (≥cT3) by endoscopy-biopsy pathology, combined with CT and/or endoscopic ultrasound;
(2) with both enhanced CT and laparoscopy;
(3) without typical peritoneal metastasis indications in CT (diffuse omental nodules or omental cake, large amount of ascites, obvious irregular thickening with high peritoneal enhancement);
(4) without other evidence of distant metastasis, and no stage IV features on CT.
Disqualifiers
(1) previous abdominal surgery;
(2) previous abdominal malignancies or inflammatory diseases;
(3) time intervals between CT and laparoscopy longer than 2 weeks;
(4) CT image artifacts that undermine peritoneal lesion assessment.
Trial design
Treatments tested in this trial
- Peritoneal metastasis status ascertainment
Treatment groups
400 Participants
are divided into 13 treatment groups13
Treatment groupsSee each treatment group below.
Sponsors and collaborators
Chinese Academy of Sciences
Lead sponsor
Peking University Cancer Hospital & Institute
Collaborator
Zhenjiang First People's Hospital
Collaborator
The First Affiliated Hospital of Zhengzhou University
Collaborator
Nanfang Hospital, Southern Medical University
Collaborator
Guizhou Provincial People's Hospital
Collaborator
Henan Cancer Hospital
Collaborator
Yunnan Cancer Hospital
Collaborator
Guangdong Provincial People's Hospital
Collaborator
Guangzhou Medical University
Collaborator
Fujian Medical University Union Hospital
Collaborator
Shanxi Province Cancer Hospital
Collaborator
Sun Yat-sen University
Collaborator
Beihang University
Collaborator
Scientific Institute San Raffaele
Collaborator
Source ClinicalTrials.gov